Original ContributionsPersistence of delays in presentation and treatment for patients with acute myocardial infarction: The GUSTO-I and GUSTO-III experience*,**
Introduction
A delay in receiving thrombolytic therapy for acute myocardial infarction (AMI) is associated with diminished treatment effect and increased mortality.1 Although treatment administered up to 12 hours after symptom onset has proved beneficial, maximum benefit is achieved when therapy is provided within the first few hours.2 Over the past decade, substantial public health efforts have successfully educated health care providers about the importance of timely treatment with thrombolytic therapy.3 As a result, the time required to identify and treat patients with myocardial infarction in the emergency setting has been nearly halved.4
Despite such success in decreasing time to treatment in the emergency department, no similar reduction in time from symptom onset to patient arrival at the hospital has been observed. In a study of all 41,021 patients enrolled in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO-I) trial, certain patient groups arrived to the hospital late in the course of their AMI.5 Female, elderly, diabetic, and hypertensive patients were found to be susceptible to delays in hospital arrival and treatment in the ED.
We hypothesized that improvement in the inhospital time to treatment for US patients with AMI would be associated with a similar decrease in the delay from symptom onset to patient arrival to the hospital. Given the publication of national guidelines on time to thrombolytic treatment and rigorous public education initiatives since 1990, the Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO-III) trial, completed in February 1997, afforded us a unique opportunity to examine this hypothesis. The parallel designs of these 2 studies also allowed us to study 2 large and very similar patient groups separated by several years in which awareness and treatment of myocardial infarction were rapidly evolving. We sought to isolate the factors associated with both out-of-hospital and inhospital delays. Furthermore, through socioeconomic information obtained in the GUSTO-III trial, we examined the impact of educational level, occupation, health care insurance status, and living alone on time delays.
Section snippets
Materials and methods
Our analysis population consisted of the patients enrolled in the United States in the GUSTO-I and GUSTO-III trials. This study was approved by the institutional review boards of all participating clinical sites. GUSTO-I enrolled 41,021 patients in a multicenter, international trial evaluating 4 fibrinolytic regimens of streptokinase and tissue plasminogen activator. Complete methods for the GUSTO-I trial have been published.6 In this trial, patients were randomized to 1 of 4 fibrinolytic
Results
The baseline characteristics of patients enrolled in GUSTO-III were similar to those of patients enrolled in GUSTO-I. Thirty-day mortality was also similar for the 2 groups (Table 1).Characteristic GUSTO-I (n=23,105) GUSTO-III (n=4,744) Age, y 61.1 (51.5, 69.8) 61.5 (51.5, 71.2) Female sex 6,278 (27.2) 1,346 (29.7) Weight, kg 80.2 (70.1, 91) 81.8 (71, 93) Height, cm 172.7 (165.1, 180) 172 (165, 179) Race Black 1,113 (4.8) 222 (4.9) Other 962 (4.2) 199
Discussion
Early treatment of patients with AMI is critical to maximizing benefit.8, 9, 10 Our study sought to identify factors associated with delays to hospital arrival as well as inhospital administration of thrombolytic therapy. In the GUSTO-I and GUSTO-III trials, the median time of delay from symptom onset to hospital arrival was 1.4 hours. During the 7 years between these 2 studies, despite widespread knowledge of the benefits of thrombolytic therapy among health care providers and extensive public
Acknowledgements
Biostatistical information is included in the full-text, online version of this article. Access the Annals Web site at www.mosby.com/AnnEmergMed. Information is also available at ACEP's home page at www.acep.org/AnnEmergMed.
Author contributions: WBG, PWA, EMO, and WDW conceived the study, designed the analysis, and supervised the conduct of the study. ALS and RMC managed the data and provided data analyses. JMG and LKN helped to recruit centers, enroll patients, and manage data. RMC and EJT
References (28)
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1,000 patients
Lancet
(1994)Halving of mortality at 1 year by domiciliary thrombolysis in the Grampian Region Early Anistreplase Trial (GREAT)
J Am Coll Cardiol
(1994)- et al.
Lay diagnosis and health-care-seeking behavior for chest pain in South Asians and Europeans
Lancet
(1997) - et al.
Survival rates and prehospital delay during myocardial infarction among black persons
Am J Cardiol
(1986) - et al.
Delay between onset of chest pain and seeking medical care: the effect of public education
Ann Emerg Med
(1989) - et al.
Time delays in the diagnosis and treatment of acute myocardial infarction: a tale of eight cities. Report from the Pre-hospital Study Group and the Cincinnati Heart Project
Am Heart J
(1990) - et al.
Prehospital diagnosis and treatment of acute myocardial infarction: a North-South perspective
Am Heart J
(1991) - et al.
Clinical features of unrecognized myocardial infarction: silent and asymptomatic. Eighteen-year follow-up: the Framingham Study
Am J Cardiol
(1973) - et al.
Influence of payer on use of invasive cardiac procedures and patient outcome after myocardial infarction in the United States
J Am Coll Cardiol
(1998) Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
Lancet
(1986)
Rapid identification and treatment of acute myocardial infarction in the emergency department
Ann Emerg Med
Treatment of myocardial infarction in the United States (1990-1993)
Circulation
Time from symptom onset to treatment and outcomes after thrombolytic therapy
J Am Coll Cardiol
An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
N Engl J Med
Cited by (107)
The relationship between symptom onset-to-needle time and ischemic outcomes in patients with acute myocardial infarction treated with primary PCI: Observations from Prague-18 Study
2022, Journal of CardiologyCitation Excerpt :Studies investigating pre-hospital delay in patients with prior CABG or MI reported conflicting results of whether patients with these comorbidities present earlier or not. In The Worcester Heart Attack Study, the researchers found that previous MI was associated with longer delays [41], while other investigators [39,40,42,43] reported significantly shorter pre-hospital delays in these patients. In a prospective cohort study performed by Coventry et al. the patients with previous MI had shorter time delay than patients without previous MI or CABG, but patients with previous MI and CABG compared with previous MI alone had longer time delays [44].
Presentation Times of Myocardial Infarctions to the Emergency Department: Disappearance of the Morning Predominance
2020, Journal of Emergency MedicineImplanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events
2019, Journal of the American College of CardiologyControversies in the Treatment of Women with ST-Segment Elevation Myocardial Infarction
2016, Interventional Cardiology Clinics
- *
Author contributions are provided at the end of this article.
- **
Address for reprints: W. Brian Gibler, MD, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0769; 513-558-8086, fax 513-558-4599;,E-mail [email protected].